Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06508762 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993
A Phase 1 study of Pain, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06508762: Completed Phase 1 study of Pain, sponsored by Vertex Pharmaceuticals Incorporated.
NCT06508762 is a Phase 1 study of Pain that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 24 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06508762, a Phase 1 study of Pain, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-993 in healthy adult participants.
Conditions Studied
Interventions
- DRUG VX-993
Study Locations (1)
Utah
- ICON Salt Lake City - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-07-26 |
| Est. Completion | 2024-09-10 |
| Phase | Phase 1 |
What the finished NCT06508762 record still lists
NCT06508762 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 1 intervention - of which VX-993 is the first listed.
NCT06508762 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06508762 about?
NCT06508762 is a clinical study titled "A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993". The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-993 in healthy adult participants.
What is the current status of trial NCT06508762?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-07-26. Estimated completion is 2024-09-10.
What conditions does trial NCT06508762 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT06508762?
The interventions under investigation include: VX-993 (DRUG).
Who is sponsoring clinical trial NCT06508762?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06508762 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06508762's enrollment target sits among peer trials
24 325th of 374 higher than 42 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
RECRUITING · Phase 1
-
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
RECRUITING · Phase 1
-
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Phase 1 Study of SBS-147 in Healthy Adults
RECRUITING · Phase 1
-
Patient Controlled Administration of Liquid Acetaminophen
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI